# Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

> **NCT00752557** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
- **DRUG:** rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
- **DRUG:** bisphosphonates, calcium, and vitamin D

## Key facts

- **NCT ID:** NCT00752557
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-03
- **Primary completion:** 2015-04-24
- **Final completion:** 2015-04-24
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752557, "Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00752557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*